Rare isolated synchronous splenic metastasis in a patient with type II papillary renal cell carcinoma

Abstract

Metastatic disease is common in renal cell carcinoma (RCC), with a third of cases being synchronous. RCC is known to metastasize to any organ in the body; however, isolated splenic metastasis is extremely rare. We report a case of synchronous splenic metastasis from type II papillary RCC with 80% sarcomatoid change. He was successfully treated with a right radical nephrectomy with en-bloc right liver resection and splenectomy with negative margins to achieve removal of the primary tumour and complete metastasectomy. He underwent 6 cycles adjuvant chemotherapy with Gemcitabine. The patient developed disease recurrence in the spine at the 6th post-operative month with a pathological fracture at T3 and cord indentation for which he underwent posterior decompression and instrumentation and palliative radiotherapy. He recovered well and remains ambulant. Surveillance scans 16 months post-surgery revealed no tumour recurrence or new metastasis.

Splenic metastasis from recurrent chromophobe renal cell carcinoma 12 years post-nephrectomy: a case report

“…A literature search on PubMed and MedLine with keywords such as splenic metastases, renal/kidney RCC metastases to the spleen was performed. At the time of writing this report, and to the best of our knowledge, there have been only 20 published reports of RCC metastases to the spleen, in the literature (Table 1) [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. Of the reports, most primaries were clear cell RCCs, only a few were of the papillary RCC subtype.…”

A survival predicting model for patients with papillary renal cell carcinoma

“…Because there is lack of granularity in SEER about type of chemotherapy and only a small number of patients had received chemotherapy (3.25%), the authors' finding that chemotherapy was a negative prognostic factor should be treated with reservation. Previous case reports showed pRCC patients with long-term cancer control by chemotherapy (5,6).…”